Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.

NCT04604067 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT04604067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04604067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 25, 2021
Completion date
December 31, 2030
Enrollment
260 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma